Circulating Biomarkers of Thyroid Cancer: An Appraisal

  • 0Department of Medicine (DMED), University of Udine, 33100 Udine, Italy.

|

|

Summary

This summary is machine-generated.

This review examines circulating biomarkers for thyroid cancer diagnosis and monitoring. It highlights the limitations of current markers and the need for new, advanced biomarkers for better clinical management.

Area Of Science

  • Endocrinology
  • Oncology
  • Biomarker Discovery

Background

  • Thyroid cancer is the most common endocrine malignancy.
  • Prognosis is influenced by cancer type and stage at diagnosis.
  • Current treatments include surgery, hormone therapy, radiation, targeted therapy, and chemotherapy.

Purpose Of The Study

  • To critically analyze the benefits and limitations of routinely measured circulating biomarkers for thyroid cancer.
  • To explore emerging circulating biomarkers for thyroid cancer diagnosis and monitoring.
  • To identify the need for a new generation of circulating biomarkers in clinical management.

Main Methods

  • Literature review of current data on thyroid cancer biomarkers.
  • Analysis of genomic, transcriptomic, and proteomic technologies for biomarker development.
  • Critical evaluation of the clinical utility of established and novel circulating biomarkers.

Main Results

  • Routine circulating biomarkers have limitations in diagnosis and monitoring of thyroid cancer.
  • Advances in omics technologies are enabling the development of novel tumor biomarkers.
  • New circulating biomarkers show promise but face challenges in clinical application.

Conclusions

  • There is a need to overcome the limitations of current circulating biomarkers for thyroid cancer.
  • Further research is required to validate and implement novel circulating biomarkers.
  • Identifying a new generation of circulating biomarkers is crucial for improved thyroid cancer management.